• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Warrant (NQ:LEXXW)

0.0062 -0.0037 (-37.37%)
Streaming Delayed Price Updated: 2:16 PM EST, Jan 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 58,117
Open 0.0043
Bid (Size) 0.0061 (100)
Ask (Size) 0.0062 (24,900)
Prev. Close 0.0099
Today's Range 0.0043 - 0.0080
52wk Range 0.0034 - 1.310
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4
December 30, 2025
Via ACCESS Newswire
News headline image
Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4
December 23, 2025
Via ACCESS Newswire

Performance

YTD
-31.9%
-31.9%
1 Month
-73.0%
-73.0%
3 Month
-84.5%
-84.5%
6 Month
-95.9%
-95.9%
1 Year
-99.0%
-99.0%

More News

Read More
News headline image
Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 16, 2025
Via ACCESS Newswire
News headline image
Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 15, 2025
Via ACCESS Newswire
News headline image
Lexaria Attending BIO International Convention
June 05, 2025
Via ACCESS Newswire
News headline image
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
February 27, 2025
Via ACCESS Newswire
News headline image
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
November 12, 2025
Via ACCESS Newswire
News headline image
Lexaria Bioscience Corp. Provides Strategic Update
October 09, 2025
Via ACCESS Newswire
News headline image
Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
September 29, 2025
Via ACCESS Newswire
News headline image
Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
September 26, 2025
Via ACCESS Newswire
News headline image
Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
September 19, 2025
Via ACCESS Newswire
News headline image
Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference
August 27, 2025
Via ACCESS Newswire
News headline image
Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone
August 14, 2025
Via ACCESS Newswire
News headline image
GLP-1 "Arms Race" Broadens to Include Dozens of Companies
August 06, 2025
Via ACCESS Newswire
News headline image
Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study
July 28, 2025
Via ACCESS Newswire
News headline image
Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry
July 23, 2025
Via ACCESS Newswire
News headline image
Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide
June 23, 2025
Via ACCESS Newswire
News headline image
Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
June 11, 2025
Via ACCESS Newswire
News headline image
Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company
May 12, 2025
Via ACCESS Newswire
News headline image
Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock
April 28, 2025
Via ACCESS Newswire
News headline image
Lexaria Announces $2 Million Registered Direct Offering of Common Stock
April 25, 2025
Via ACCESS Newswire
News headline image
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology
April 23, 2025
Via ACCESS Newswire
News headline image
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
April 03, 2025
Via ACCESS Newswire
News headline image
Lexaria's Human GLP-1 Study #5 Begins Dosing
April 02, 2025
Via ACCESS Newswire
News headline image
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)
March 18, 2025
Via ACCESS Newswire

Frequently Asked Questions

Is Lexaria Bioscience Corp. - Warrant publicly traded?
Yes, Lexaria Bioscience Corp. - Warrant is publicly traded.
What exchange does Lexaria Bioscience Corp. - Warrant trade on?
Lexaria Bioscience Corp. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for Lexaria Bioscience Corp. - Warrant?
The ticker symbol for Lexaria Bioscience Corp. - Warrant is LEXXW on the Nasdaq Stock Market
What is the current price of Lexaria Bioscience Corp. - Warrant?
The current price of Lexaria Bioscience Corp. - Warrant is 0.0062
When was Lexaria Bioscience Corp. - Warrant last traded?
The last trade of Lexaria Bioscience Corp. - Warrant was at 01/08/26 02:16 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap